This page shows what was measured, who it was measured in, and what that does not settle.
What Atezolizumab does in the body
Metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy
From the FDA-approved label: PD L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. 1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production. 1 receptors. This releases the PD L1/PD 1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as protein.
FDA substance registry · 52CMI0WC3Y · read 2026-08-29
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 103 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Protein
A protein is a folded chain your body builds to do a specific job.
A picture of it, and where the picture fails
A protein is like a tool bent into one shape for one task.
Where that stops being true. A tool keeps its shape. A protein can change shape and stop working.
What people get wrong. Protein in food and a protein in the body are related but not the same thing.
A polymer of amino acids folded into a defined structure that determines its function.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Correlation between Adverse events (AEs) and gene profile
✗ The study did not show it
Who was studied
NCT05055908
How many people
12000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
✗ The study did not show it
Who was studied
NCT07620574
How many people
5000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
✗ The study did not show it
Who was studied
NCT02693535
How many people
4200
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
16 weeks clinical response
✗ The study did not show it
Who was studied
NCT04817956
How many people
3000
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Invasive Disease-Free Survival (iDFS)
✗ The study did not show it
Who was studied
NCT03498716
How many people
2199
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
Event-free survival (EFS)
✗ The study did not show it
Who was studied
NCT03281954
How many people
1550
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Injection
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
FDA label (openFDA SPL) · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.7 registered measures of this kind. 2 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
□A number that stands in for healthNo evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.No registered study measures this.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
No registered study measured anything of this kind.
Meaningful
Things that change how a life goes, not only a number.
disease free survival
overall survival
progression free survival
overall survival in the itt population
disease free survival as assessed by investigator
event free survival
relapse free survival
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (33)
adverse events and serious adverse events
dose limiting toxicities
adverse events
dose escalation cohorts number of dose limiting toxicities
part b durable response rate
incidence of adverse events
incidence of dose limiting toxicities
infusion related reactions
forced expiratory volume
forced vital capacity
log2 over time
objective response rate
dlts
rcb status
maximum tolerated dose
major pathologic response
best overall response rate
minimal residual disease negative rate
pathologic complete response rate
phase 1 number of experiencing dose limiting toxicities
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 27 days
Read from the label, which states: “Elimination The clearance (CV%) is 0.2 L/day (29%) and the terminal half-life is 27 days.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of TECENTRIQ for ASPS have not been established in pediatric patients younger than 2 years of age.”
US prescribing information · 6fa682c9-a312-4932-9831-f286908660ee · read 2026-08-30
On older people, the label states: “TECENTRIQ as a Single-Agent Of 2616 patients with metastatic NSCLC and other tumor types treated with single agent TECENTRIQ in clinical studies, 49% were 65 years and over and 15% were 75 years and over.”
US prescribing information · 6fa682c9-a312-4932-9831-f286908660ee · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on its mechanism of action [see Clinical Pharmacology (12.1) ] , TECENTRIQ can cause fetal harm when administered to a pregnant woman.”
US prescribing information · 6fa682c9-a312-4932-9831-f286908660ee · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of atezolizumab in human milk, the effects on the breastfed infant, or the effects on milk production.”
US prescribing information · 6fa682c9-a312-4932-9831-f286908660ee · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Injection
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4.
No source is stored against this line.
What is in the pack
Sold as injectable, injection, injection, solution, given by the injection, subcutaneous, intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Atezolizumab appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 4877 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Injection
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
4 products list this as an active ingredient in the United States drug directory. 3 of them contain it and nothing else.
FDA National Drug Code directory · 50242-917 · read 2026-08-29
They are sold as injection, injection, solution and liquid, taken intravenous and subcutaneous.
FDA National Drug Code directory · 50242-917 · read 2026-08-29
The regulator's established pharmacologic class for it is antibodies, antibodies [cs] and humanized [cs].
FDA National Drug Code directory · 50242-917 · read 2026-08-29
2 published labels name it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · a617b089-ce66-464b-987b-b45d029b4d6f · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · a617b089-ce66-464b-987b-b45d029b4d6f · read 2026-08-29
TECENTRIQ is intravenous at 3 DOSAGE FORMS AND STRENGTHS Injection: 840 mg/14 mL (60 mg/mL) and 1200 mg/20 mL (60 mg/mL) colorless to slightly yellow solution in a single-dose vial., recorded as fda label in effect 2026-05-20 in the United States.
US prescribing information · 6fa682c9-a312-4932-9831-f286908660ee · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Atezolizumab studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Atezolizumab are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
52CMI0WC3Y
RxNorm concept
1792780
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
2 approved applications cover products containing this substance. The earliest was BLA761034, approved 20160518 to GENENTECH INC.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (12)
Q2
What did Atezolizumab's largest trial (5279 people) and its longest (24 years) measure?
5279 people in Atezolizumab's largest registered study, 24 years in its longest registered window, measuring BTCT4465A (Mosunetuzumab) Serum Concentration. ClinicalTrials.gov · 2026-09-01
402 phase2, 232 phase1, 114 phase3, 30 na or unstated, 10 early phase1, 7 phase4, 2 na; NCT04817956; 2045-04-30; no ageing endpoint recorded. Last human test completed 2026, NCT03782207.
Interpretation These counts include studies where Atezolizumab was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
402
phase1
232
phase3
114
na or unstated
30
early phase1
10
phase4
7
2 more recorded rows
na
2
Last recorded human testNCT03782207
2026-07-31
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Atezolizumab shown lifespan?
terminated; "Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention."
NCT02303951
terminated; "The main reason for the early termination is the low recruitment rate."
NCT02322814
terminated; "Sponsor's decision"
NCT02400814
terminated; "Enrollment halted due to slow accrual."
NCT02409355
terminated; "The study was closed due to low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study, NCT02409342."
14 further recorded trials
NCT02450331
terminated; "Sponsor decided to terminate the study early because the study did not meet its primary endpoint and because the study had met its goals of providing safety and additional exploratory efficacy information for atezolizumab monotherapy in…"
NCT02495636
withdrawn; "Study closed due to lack of enrollment"
NCT02541604
terminated; "Sponsor decision to terminate because limited investigational agent activity was observed."
NCT02609984
terminated; "This study did not meet the efficacy objective"
NCT02630186
terminated; "The study terminated before Phase 1 was completed. This study was reprioritized within the rociletinib development program."
NCT02748889
terminated; "Difficulties with recruitment"
NCT02784483
terminated; "Based on FDA requirements"
NCT02792192
terminated; "The study was terminated early as the study had met its goals of providing preliminary safety and efficacy information for atezolizumab monotherapy alone and in combination with BCG in NMIBC."
NCT02919449
terminated; "Low recruitment"
NCT02982694
terminated; "The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) is inferior to the expected, and this situation is very unlikely to be reversed if the trial is fully completed."
NCT03024437
terminated; "Genentech has closed the study due to lack of data with Atezo"
NCT03024996
terminated; "The sponsor decided to terminate this study before the protocol-defined end-of-study, as permitted per protocol."
NCT03029832
terminated; "The study was prematurely terminated due to slow patient accrual and discontinuation of clinical development of MOXR0916 due to Sponsor's strategic priorities."
NCT03050060
terminated; "Terminated due to slow accrual"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Atezolizumab used Atezolizumab (1200mg via IV infusion) — over how long?
10 recorded entries; human; IV; also "Atezolizumab (1200mg via IV infusion)", "Atezolizumab 1200 MG in 20 ML Injection", "Atezolizumab (1200 mg every three weeks)"
Show the evidence
human
NCT02784483
IV; Atezolizumab (1200mg via IV infusion)
NCT04081688
Atezolizumab 1200 MG in 20 ML Injection
NCT04160494
Atezolizumab (1200 mg every three weeks)
NCT04400474
Atezolizumab 1200 mg
NCT04423185
Atezolizumab 1680 MG
NCT04487756
Atezolizumab 1200 mg in 20 ML Injection
4 more recorded rows
humanNCT04602078
Atezolizumab 1200 mg/m2
humanNCT04770272
Atezolizumab 840 MG in 14 ML Injection
humanNCT04808245
Tecentriq 1200 MG in 20 ML Injection
humanNCT04962126
Atezolizumab 1200 MG/40mL Intravenous Solution
recorded 2026-09-01 · last checked 2026-09-04
Q6
Atezolizumab's half-life is 27 days — which schedules were studied?
27 days, the half-life Atezolizumab's label states. openfda-label · 6fa682c9-a312-4932-9831-f286908660ee · 2026-08-30
Show the evidence
half life
27 days; Elimination The clearance (CV%) is 0.2 L/day (29%) and the terminal half-life is 27 days.
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of adverse events, adverse events and serious adverse events and best overall response did Atezolizumab's trials measure?
adverse events, adverse events and serious adverse events and best overall response lead 40 outcome terms across Atezolizumab's trials. ClinicalTrials.gov · 2026-09-01
Interpretation disease free survival, overall survival, dose escalation cohorts number of dose limiting toxicities, part b durable response rate, progression free survival and incidence of adverse events follow.
Show the evidence
adverse events and serious adverse events
1
dose limiting toxicities
1
adverse events
1
disease free survival
1
overall survival
1
dose escalation cohorts number of dose limiting toxicities
1
14 more recorded rows
part b durable response rate
1
progression free survival
1
incidence of adverse events
1
incidence of dose limiting toxicities
1
infusion related reactions
1
forced expiratory volume
1
forced vital capacity
1
overall survival in the itt population
1
disease free survival as assessed by investigator
1
log2 over time
1
objective response rate
1
dlts
1
rcb status
1
maximum tolerated dose
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Atezolizumab's 277 ongoing trials reports first?
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs); Validate the BRCA1-like test; latest 2045-04-30
Show the evidence
Trial
NCT00781612
"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies"; n 378; "Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)"; 2027-06-30
NCT01898117
"Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer"; n 304; "Validate the BRCA1-like test"; 2030-12
NCT02486718
"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]"; n 1280; "Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population"; 2027-08-31
NCT02525757
"MPDL3280A With Chemoradiation for Lung Cancer"; n 52; "Time to Toxicity"; 2028-01-31
NCT02839707
"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"; n 444; "Incidence of Dose Limiting Toxicities (DLT) of Experimental Regimens"; 2027-05-11
NCT02846623
"Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome"; n 50; "Minimal residual disease (MRD) negative rate (Cohort I)"; 2027-02-28
14 further recorded trials
NCT02849496
"Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer"; n 89; "Progression-free survival (PFS)"; 2027-08-26
NCT02862275
"Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer"; n 40; "Incidence of adverse events"; 2026-11-21
NCT02883062
"Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer"; n 67; "Change in Tumor Infiltrating Lymphocyte (TIL) Percentage"; 2026-09-11
NCT02912559
"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair"; n 712; "Disease Free Survival (DFS)"; 2026-12-18
NCT02935361
"Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed"; n 33; "Incidence of dose-limiting toxicities evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)"; 2027-12-31
NCT02989584
"A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer"; n 54; "Test the safety of atezolizumab in combination with gemcitabine/cisplatin as assessed by dose limiting toxicity rate."; 2026-12
NCT02997228
"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study"; n 120; "Progression free survival (PFS)"; 2027-06-01
NCT03074513
"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors"; n 133; "Objective response"; 2027-09-30
NCT03093922
"A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer"; n 32; "overall response rate"; 2027-03
NCT03125928
"Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer"; n 16; "Number of participants with treatment-related adverse events"; 2027-12
NCT03141684
"Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma"; n 63; "Objective response rate"; 2026-10-31
NCT03148418
"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)"; n 382; "Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)"; 2026-12-31
NCT03170960
"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors"; n 914; "Dose Escalation: MTD/Recommended Dose"; 2027-09-30
NCT03175432
"Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases"; n 29; "Objective intracranial response rate (OIRR) as measured by the modified immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria"; 2028-06-30
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Atezolizumab could settle lifespan?
NCT06780826 measures progression free survival, reading out 2025-09-30.
81 open trials; n 1430; "A Study on the Efficacy of Atezolizumab Combined with Chemotherapy"
Show the evidence
Trial
NCT06780826
"A Study on the Efficacy of Atezolizumab Combined with Chemotherapy"; n 1430; "progression free survival"; 2025-09-30
NCT06323382
"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma"; n 240; "Progression-Free-Survival (PFS)"; 2025-12-30
NCT05781308
"Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy"; n 156; "Progression Free Survival at 6 months determined by independent reviewer"; 2026-06
NCT04665856
"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer"; n 123; "Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set (PAS)"; 2026-06-30
NCT03755791
"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy"; n 837; "Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population"; 2026-07-31
NCT04563338
"An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)"; n 36; "Progression-free survival"; 2026-08-31
14 further recorded trials
NCT05904886
"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)"; n 687; "Investigator-assessed Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)"; 2026-09-01
NCT05689671
"Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma"; n 136; "Overall Survival (OS)"; 2026-10
NCT04660344
"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy"; n 761; "Investigator-assessed (INV) - Disease-free Survival (DFS)"; 2026-10-01
NCT04770896
"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab"; n 557; "Overall Survival (OS)"; 2026-10-14
NCT04446117
"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC"; n 575; "Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)"; 2026-10-16
NCT05798663
"Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC"; n 178; "To determine the progression-free survival (PFS) of patients treated with neoadjuvant, concurrent and adjuvant atezolizumab with or without tiragolumab."; 2026-11
NCT03977194
"Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy"; n 510; "Overall Survival"; 2026-12
NCT06117891
"An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery"; n 300; "Overall survival (OS)"; 2026-12-10
NCT02912559
"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair"; n 712; "Disease Free Survival (DFS)"; 2026-12-18
NCT05168163
"Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer"; n 122; "Overall survival (OS)"; 2026-12-31
NCT03463057
"The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL"; n 109; "Disease free survival (DFS) measured from the date of registration to relapse or death from any cause whichever comes first."; 2027-01
NCT04334941
"Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker"; n 103; "Progression free survival"; 2027-01-21
NCT05047250
"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer"; n 60; "Overall survival (OS)"; 2027-01-29
NCT05425940
"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer"; n 901; "Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized Participants"; 2027-01-31
Q10
Which 79 trials of Atezolizumab posted no result?
Posted no result
79 of 79 completed trials
Registrations
NCT01375842, NCT02463994, NCT03330886, NCT02508870, NCT02876224 and NCT03087864, and 73 more
Completion dates
oldest 2018-09-30; newest 2024-09-02
Show the evidence
Trial
NCT01375842
2018-09-30
NCT02463994
2018-11-07
NCT03330886
2019-03-02
NCT02508870
2019-06-10
NCT02876224
2019-06-25
NCT03087864
2019-07-01
14 further recorded trials
NCT02814669
2019-07-31
NCT02471846
2019-10-02
NCT01988896
2019-11-04
NCT02304393
2019-11-07
NCT02605915
2019-11-13
NCT02410512
2019-11-22
NCT02174172
2019-11-25
NCT03438318
2019-12-11
NCT02892318
2019-12-12
NCT02350673
2019-12-16
NCT02650713
2020-01-13
NCT02220842
2020-01-21
NCT02013219
2020-02-05
NCT01633970
2020-02-26
Q11
At the median, Atezolizumab's trials enrolled 60 people — anything larger?
Median enrolment
60
Largest enrolment
5279
Registered trials counted
680
Q12
What do 4877 spontaneous reports say about Atezolizumab — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Atezolizumab appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 4877 reaction mentions were counted: pyrexia 932; pneumonitis 571; febrile neutropenia 521; interstitial lung disease 521. open-targets-adr · CHEMBL3707227 · 2026-06-24
Show the evidence
pyrexia
932
pneumonitis
571
febrile neutropenia
521
interstitial lung disease
521
disease progression
510
hypothyroidism
421
4 more recorded rows
radiation pneumonitis
384
hepatic function abnormal
357
colitis
355
neutrophil count decreased
305
recorded 2026-06-24 · last checked 2026-09-04
Q13
What is recorded about Atezolizumab and autophagy?
"Further research revealed that CQ upregulated PD-L1 protein levels by decreasing its autophagic degradation and that the PD-L1 inhibitor atezolizumab reversed the decrease in CD8<sup>+</sup> T cell infiltration caused by CQ in FAT1-L AML cells." — where Atezolizumab and autophagy appear together. Europe PMC · pathway abstract search · 2025-06-04
"Further research revealed that CQ upregulated PD-L1 protein levels by decreasing its autophagic degradation and that the PD-L1 inhibitor atezolizumab reversed the decrease in CD8<sup>+</sup> T cell infiltration caused by CQ in FAT1-L AML cells."
PMID 36811581
"The PD-L1-inhibitor atezolizumab synergized with panobinostat (DACi) and sorafenib (MKI) leading to significant reduction of the viability, measured by real time luminescence, of three different patient-derived primary ATC cells, of C643 cells and follicular epithelial thyroid cells too. <i>Solo</i> administration of these compounds caused a significant over-expression of autophagy transcripts;…"
PMID 36374537
"In this work, to exploit the lysosome escape and autophagy-inducing properties of JEV for cancer therapy, we constructed a virus-mimicking nanodrug consisting of anti-PDL1 antibody-decorated JEV-mimicking virosome encapsulated with a clinically available autophagy inhibitor, hydroxychloroquine (HCQ)."
mTOR
PMID 40468525
"Tumor DNA from newly acquired biopsies or ctDNA were analyzed for alterations targetable with the PD-L1 inhibitor atezolizumab, the MEK inhibitor cobimetinib, the mTOR inhibitor everolimus, or the PARP-inhibitor niraparib."
PMID 39796641
"Examples are the tyrosine kinase inhibitors avapritinib and ripretinib in gastrointestinal stromal tumours (GIST), the immune check point inhibitor atezolizumab in alveolar soft part tissue sarcoma, the γ-secretase inhibitor nirogacestat in desmoid tumours, the NTRK inhibitors larotrectinib and entrectinib in tumours with <i>NTRK</i> fusions, the mTOR inhibitor nab-sirolimus in PEComa, and the…"
recorded 2025-06-04 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.